Cancer- and chemotherapy-induced anemia: Clinical practice guidelines in oncology

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 5, 2012, Pages 628-653

  Rodgers III, George M ^a   Becker, Pamela Sue ^b   Blinder, Morey ^c   Cella, David ^d   Chanan Khan, Asher ^e   Cleeland, Charles ^f   Coccia, Peter F ^g   Djulbegovic, Benjamin ^h   Gilreath, Jeffrey A ^a   Kraut, Eric H ⁱ   Matulonis, Ursula A ^j   Millenson, Michael M ^k   Reinke, Denise ^l   Rosenthal, Joseph ^m   Schwartz, Rowena N ⁿ   Soff, Gerald ^o   Stein, Richard S ^p   Vlahovic, Gordana ^q   Weir III, Alva B ^r  

^a UNIVERSITY OF UTAH   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

^c BARNES JEWISH HOSPITAL   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g NEBRASKA MEDICAL CENTER   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ OHIO STATE UNIVERSITY   (United States)

^j Dana Farber/Brigham and Women's Cancer Center   (United States)

^k FOX CHASE CANCER CENTER   (United States)

^l UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^m CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁿ JOHNS HOPKINS UNIVERSITY   (United States)

^o MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^p VANDERBILT INGRAM CANCER CENTER   (United States)

^q DUKE CANCER INSTITUTE   (United States)

^r UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERRITIN; HEMOGLOBIN; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ARTERIAL THROMBOEMBOLISM; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL PRACTICE; CRITICALLY ILL PATIENT; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DYSPNEA; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEALTH STATUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MEAN CORPUSCULAR VOLUME; MENSTRUATION DISORDER; MORTALITY; OVERALL SURVIVAL; PRIMARY TUMOR; RADIATION EXPOSURE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SYNCOPE; THORAX PAIN; TREATMENT RESPONSE; TUMOR GROWTH; VEIN THROMBOSIS; VERTIGO;

EID: 84861818190     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0064     Document Type: Review

References (86)

1. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004;116(Suppl 7A):11S-26S.
2. Schwartz RN. Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols. Am J Health Syst Pharm 2007;64:S5-13; quiz S28-30.
3. Steensma DP. Is anemia of cancer different from chemotherapy-induced anemia? J Clin Oncol 2008;26:1022-1024.
4. Wilson J, Yao GL, Raftery J, et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007;11:1-202, iii-iv.
5. Moullet I, Salles G, Ketterer N, et al. Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann Oncol 1998;9:1109-1115. (Pubitemid 28518150)
6. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-2306. (Pubitemid 39348881)
7. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634. (Pubitemid 29479929)
8. Jefferies S, Rajan B, Ashley S, et al. Haematological toxicity of cranio-spinal irradiation. Radiother Oncol 1998;48:23-27. (Pubitemid 28391964)
9. Glaus A, Crow R, Hammond S. A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Support Care Cancer 1996;4:82-96. (Pubitemid 126469092)
10. Miller Y, Bachowski G, Benjamin R, et al. Practice guidelines for blood transfusion: a compilation from recent peer-reviewed literature, 2nd edition. Washington, DC; American Red Cross; 2007. Available at: http://www.redcross.org/ www-files/Documents/WorkingWiththeRedCross/practiceguidelinesforbloodtrans.pdf. Accessed April 1, 2012.
11. Wiesen AR, Hospenthal DR, Byrd JC, et al. Equilibration of hemoglobin concentration after transfusion in medical inpatients not actively bleeding. Ann Intern Med 1994;121:278-230.
12. Kader AS, Lim JT, Berthelet E, et al. Prognostic significance of blood transfusions in patients with esophageal cancer treated with combined chemoradiotherapy. Am J Clin Oncol 2007;30:492-497. (Pubitemid 47537949)
13. Spivak JL, Gascon P, Ludwig H. Anemia management in oncology and hematology. Oncologist 2009;14(Suppl 1):43-56.
14. Hill SR, Carless PA, Henry DA, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2002:CD002042.
15. Blajchman MA, Vamvakas EC. The continuing risk of transfusion-transmitted infections. N Engl J Med 2006;355:1303-1305. (Pubitemid 44465458)
16. King KE, Shirey RS, Thoman SK, et al. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs. Transfusion 2004;44:25-29. (Pubitemid 38177132)
17. Yazer MH, Podlosky L, Clarke G, Nahirniak SM. The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. Transfusion 2004;44:10-15. (Pubitemid 38177130)
18. Khorana AA, Francis CW, Blumberg N, et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008;168:2377-2381.
19. Jabbour E, Kantarjian HM, Koller C, Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer 2008;112:1089-1095. (Pubitemid 351304594)
20. Vekeman F, Bookhart BK, White J, et al. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. Transfusion 2009;49:895-902.
21. Pawson R, Brunskill S, Murphy MF, et al. Different threshold levels for red blood cell transfusions in patients with haematological malignancy (Protocol). Cochrane Database Syst Rev 2006;3:CD006166.
22. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999;340:409-417. (Pubitemid 29084771)
23. Steinbrook R. Erythropoietin, the FDA, and oncology. N Engl J Med 2007;356:2448-2451. (Pubitemid 46919769)
24. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874. (Pubitemid 32538196)
25. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-1220. (Pubitemid 34993871)
26. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-714. (Pubitemid 43821788)
27. Food and Drug Administration. Epoetin alfa label. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/103234Orig1s5166- 103234Orig1s5266lbl.pdf. Accessed January 25, 2012.
28. Food and Drug Administration. Darbepoetin alfa label. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/103951Orig1s5173- 103951Orig1s5258lbl.pdf. Accessed January 25, 2012.
29. Untch M, Fasching PA, Bauerfeind I, et al. PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin/cyclophosphamide followed by paclitaxel {+/-} darbepoetin alfa in primary breast cancer: a preplanned interim analysis of efficacy at surgery [abstract]. J Clin Oncol 2008;26(Suppl 15):Abstract 517.
30. Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403. (Pubitemid 36951623)
31. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260. (Pubitemid 37324251)
32. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-5972.
33. Overgaard J, Hoff CM, Hansen HS, et al. Randomized study of darbepoetin alfa as modifier of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): final outcome of the DAHANCA 10 trial [abstract]. J Clin Oncol 2009;27(Suppl 15):Abstract 6007.
34. Smith RE Jr, Aapro MS, Ludwig H, et al. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26:1040-1050.
35. Thomas G, Ali S, Hoebers FJ, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008;108:317-325.
36. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027-1032. (Pubitemid 46596751)
37. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-924. (Pubitemid 351397066)
38. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532-1542.
39. Tonelli M, Hemmelgarn B, Reiman T, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009;180:E62-71.
40. Bennett CL, Henke M, Lai SY. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia - reply. JAMA 2008;300:2855-2857.
41. Ludwig H, Crawford J, Osterborg A, et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009;27:2838-2847.
42. Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010;102:301-315.
43. Engert A, Josting A, Haverkamp H, et al. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol 2010;28:2239-2245.
44. Moebus V, Jackisch C, Lueck HJ, et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 2010;28:2874-2880.
45. Untch M, Fasching PA, Konecny GE, et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel {+/-} darbepoetin alfa in primary breast cancer: results at the time of surgery. Ann Oncol 2011;22:1988-1998.
46. Pirker R, Ramlau RA, Schuette W, et al. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol 2008;26:2342-2349.
47. Grote T, Yeilding AL, Castillo R, et al. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2005;23:9377-9386.
48. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-815. (Pubitemid 30165241)
49. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632-634. (Pubitemid 46680709)
50. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404-407. (Pubitemid 18044179)
51. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286-294.
52. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490-5505. (Pubitemid 350232226)
53. Glaspy J, Osterborg A, Ludwig H, et al. Evaluation of the association between hemoglobin (Hb) events and safety outcomes in cancer patients (pts) with chemotherapy-induced anemia (CIA): an integrated analysis of patient-level data from 6 randomized, placebo-controlled trials (RCTs) of darbepoetin [abstract]. Eur J Cancer Suppl 2007;5:Abstract 147.
54. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-2032.
55. Food and Drug Administration. FDA information on ESAs. 2010. Available at: http://www.fda.gov/cder/drug/infopage/RHE/. Accessed January 25, 2012.
56. Bennett CL, Cournoyer D, Carson KR, et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 2005;106:3343-3347. (Pubitemid 41609162)
57. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004;351:1403-1408. (Pubitemid 39288166)
58. McKoy JM, Stonecash RE, Cournoyer D, et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008;48:1754-1762.
59. Food and Drug Administration. FDA on ESA-associated PRCA. 2006. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/printer.cfm?id=430. Accessed January 25, 2012.
60. Bennett CL, Becker PS, Kraut EH, et al. Intersecting guidelines: administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer. Semin Dial 2009;22:1-4.
61. Ballen KK, Becker PS, Yeap BY, et al. Autologous stem-cell transplantation can be performed safely without the use of blood-product support. J Clin Oncol 2004;22:4087-4094. (Pubitemid 41185177)
62. Ballen KK, Ford PA, Waitkus H, et al. Successful autologous bone marrow transplant without the use of blood product support. Bone Marrow Transplant 2000;26:227-229. (Pubitemid 30496973)
63. Brown NM, Kim SY, Ford PA. Autologous stem cell transplants in Jehovah's Witnesses. Bone Marrow Transplant 2009;44:391-392.
64. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-1234. (Pubitemid 27106310)
65. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882. (Pubitemid 32538197)
66. Henry DH, Gordan LN, Charu V, et al. Randomized, open-label comparison of epoetin alfa extended dosing (80,000 U Q2W) vs weekly dosing (40,000 U QW) in patients with chemotherapy-induced anemia. Curr Med Res Opin 2006;22:1403-1413. (Pubitemid 44085592)
67. Steensma DP, Molina R, Sloan JA, et al. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol 2006;24:1079-1089. (Pubitemid 46638805)
68. Canon JL, Vansteenkiste J, Bodoky G, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273-284. (Pubitemid 43264711)
69. Thames WA, Smith SL, Scheifele AC, et al. Evaluation of the US Oncology Network's recommended guidelines for therapeutic substitution with darbepoetin alfa 200 microg every 2 weeks in both naive patients and patients switched from epoetin alfa. Pharmacotherapy 2004;24:313-323. (Pubitemid 38298756)
70. Boccia R, Malik IA, Raja V, et al. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist 2006;11:409-417.
71. Henry DH. Supplemental iron: a key to optimizing the response of cancer-related anemia to rHuEPO? Oncologist 1998;3:275-278. (Pubitemid 28399654)
72. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-1023.
73. Silverstein SB, Gilreath JA, Rodgers GM. Intravenous iron therapy: a summary of treatment options and review of guidelines. J Pharm Pract 2008;21:431-443.
74. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-1307. (Pubitemid 41079845)
75. Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26:1611-1618.
76. Hedenus M, Birgegard G, Nasman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007;21:627-632. (Pubitemid 46444544)
77. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231-242.
78. Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008;26:1619-1625.
79. Steensma DP, Sloan JA, Dakhil SR, et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 2011;29:97-105.
80. Mhaskar R, Wao H, Kumar A, et al. Role of iron supplementation to erythropoiesis stimulating agents in the management of chemotherapy-induced anemia in cancer patients: a systematic review and meta-analysis [abstract]. Blood 2010;116(Suppl 21):Abstract 2055.
81. National Institutes of Health. Ferrlecit package insert. Available at: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a2f2f298-2dec-4020-97c8- 2aade4b99b2e. Accessed January 25, 2012.
82. National Institutes of Health. Venofer package insert. Available at: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=626dc9e5-c6b4-4f9c-9bf4- 774fd3ae619a. Accessed January 25, 2012.
83. Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hematol 2004;76:74-78. (Pubitemid 38579543)
84. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006;21:378-382. (Pubitemid 43159991)
85. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet 2007;369:1502-1504. (Pubitemid 46670290)
86. Lapointe M. Iron supplementation in the intensive care unit: when, how much, and by what route? Crit Care 2004;8(Suppl 2):S37-41. (Pubitemid 39144729)